2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2008040402v1 20/5/933    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schlaich, M. P. Articles by Lambert, G. W. Search for Related Content PubMed PubMed Citation Articles by Schlaich, M. P. Articles by Lambert, G. W.

Sympathetic Activation in Chronic Renal Failure

Neurovascular Hypertension and Kidney Disease Laboratory, Baker Heart Research Institute, Melbourne, Australia

Correspondence: Prof. Markus P. Schlaich, Neurovascular Hypertension & Kidney Disease Laboratory, Baker Heart Research Institute, P.O. Box 6492 St. Kilda Road Central, Melbourne VIC 8008, Australia. Phone: ++61-3-8532-1502; Fax: ++61-3-8532-1100; E-mail: markus.schlaich{at}baker.edu.au

The potential involvement of sympathetic overactivity has been neglected in this population despite accumulating experimental and clinical evidence suggesting a crucial role of sympathetic activation for both progression of renal failure and the high rate of cardiovascular events in patients with chronic kidney disease. The contribution of sympathetic neural mechanisms to the occurrence of cardiac arrhythmias, the development of hypertension, and the progression of heart failure are well established; however, the exact mechanisms contributing to heightened sympathetic tone in patients with chronic kidney disease are unclear. This review analyses potential mechanisms underlying sympathetic activation in chronic kidney disease, the range of adverse consequences associated with this activation, and potential therapeutic implications resulting from this relationship.

This article has been cited by other articles:

				M. Baumann, K. Leineweber, M. Tewiele, K. Wu, T. R. Turk, S. Su, M. Gossl, T. Buck, B. Wilde, U. Heemann, et al. Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function Nephrol. Dial. Transplant., January 7, 2010; (2010) gfp708v1. [Abstract] [Full Text] [PDF]

				N. E. Straznicky, E. A. Lambert, P. J. Nestel, M. T. McGrane, T. Dawood, M. P. Schlaich, K. Masuo, N. Eikelis, B. de Courten, J. A. Mariani, et al. Sympathetic Neural Adaptation to Hypocaloric Diet With or Without Exercise Training in Obese Metabolic Syndrome Subjects Diabetes, January 1, 2010; 59(1): 71 - 79. [Abstract] [Full Text] [PDF]

				F. C. Luft Not so free associations Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3576 - 3577. [Full Text] [PDF]

				E. Ritz, H Krum, M Schlaich, R Whitbourn, P. Sobotka, J Sadowski, K Bartus, B Kapelak, A Walton, H Sievert, et al. New Approaches to Pathogenesis and Management of Hypertension Clin. J. Am. Soc. Nephrol., December 1, 2009; 4(12): 1886 - 1891. [Full Text] [PDF]

				M. P. Schlaich, P. A. Sobotka, H. Krum, R. Whitbourn, A. Walton, and M. D. Esler Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept Hypertension, December 1, 2009; 54(6): 1195 - 1201. [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673